Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

65.28EUR
20 Apr 2018
Change (% chg)

€-0.32 (-0.49%)
Prev Close
€65.60
Open
€65.20
Day's High
€65.95
Day's Low
€65.08
Volume
3,237,572
Avg. Vol
2,724,311
52-wk High
€92.97
52-wk Low
€62.88

Select another date:

Thu, Apr 19 2018

Photo

WHO recommends testing before use of Sanofi's dengue vaccine

PARIS/CHICAGO The World Health Organization (WHO) said on Thursday Sanofi's vaccine against dengue should only be used after testing on individuals to assess whether they have ever been exposed to the infection.

UPDATE 2-WHO recommends testing before use of Sanofi's dengue vaccine

* Sanofi confident in vaccine's safety (Changes headline, adds Sanofi comment)

BRIEF-Sanofi confident in Dengvaxia's safety and potential

* SANOFI SAYS CONFIDENT IN DENGVAXIA’S SAFETY AND PROVEN POTENTIAL TO REDUCE DENGUE DISEASE BURDEN IN ENDEMIC COUNTRIES

Sanofi's CFO Contamine to retire later this year

PARIS Sanofi's executive vice president and chief financial officer, Jerome Contamine, plans to retire later this year, the French drugmaker said on Tuesday.

Sanofi's CFO Contamine to retire later this year

PARIS, April 17 Sanofi's executive vice president and chief financial officer, Jerome Contamine, plans to retire later this year, the French drugmaker said on Tuesday.

Sanofi in talks to sell generics arm to Advent for $2.4 billion

PARIS French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion), the companies said on Tuesday. | Video

UPDATE 2-Sanofi in talks to sell generics arm to Advent for $2.4 bln

* Healthcare sector has seen lots of M&A so far in 2018 (Adds detail)

Sanofi in talks to sell generics arm Zentiva to Advent for 1.9 bln euros

PARIS, April 17 French healthcare group Sanofi has started exclusive talks with private equity firm Advent International over selling its Zentiva European generics drugs arm to Advent for 1.9 billion euros ($2.4 billion), the companies said.

France's Sanofi sells 12 brands to Charterhouse's Cooper-Vemedia

PARIS French healthcare and drugs group Sanofi has agreed to sell a portfolio of 12 pharmaceutical brands to Charterhouse Capital Partners' Cooper-Vemedia drugs manufacturing arm for 158 million euros ($195 million), the companies said on Monday.

France's Sanofi sells 12 brands to Charterhouse's Cooper-Vemedia

PARIS, April 16 French healthcare and drugs group Sanofi has agreed to sell a portfolio of 12 pharmaceutical brands to Charterhouse Capital Partners' Cooper-Vemedia drugs manufacturing arm for 158 million euros ($195 million), the companies said on Monday.

Select another date: